Miniatura

Fitxers

PIIS2468024925004292.pdf (1.31 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-07-08

Llicència de publicació

cc-by-nc-nd (c) International Society of Nephrology, 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/223518

A New Prognostic Score Based on Cell-Mediated Immunity for Cytomegalovirus Infection After Transplantation

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.ekir.2025.06.056

Resum

Introduction: The interferon gamma (IFN-g) enzyme-linked immunosorbent spot is a highly sensitive immune assay that enables the assessment of cytomegalovirus (CMV)-specific cell-mediated immunity (CMI) and can identify at-risk transplant patients of CMV infection; however, its clinical implementation remains elusive. Methods: We developed a novel CMV-CMI risk-score based on the standardized T-SPOT.CMV assay against 2 CMV antigens (immediate-early protein 1 [IE-1] and 65 kDa phosphoprotein [pp65]), a biomarker predicting CMV infection, both high viral replication, and disease by performing a pooled analysis of 570 kidney transplants participating in different clinical trials and subsequently validating it in 146 consecutives solid organ transplants (SOT) in an interventional trial. By incorporating clinical variables into the CMV-CMI risk-score, we built an integrative prognostic system quantifying the risk of CMV infection (CMV-PrognosTIC score) using elastic net penalized regression analysis. Results: In the pooled derivation cohort, whereas specific IE-1/pp65-specific CMV-CMI frequencies independently correlated with high risk of CMV infection (areas under the curve [AUCs]: 0.694, P < 0.0001; 0.719, P < 0.0001, respectively), by combining both responses, 3 CMV-CMI risk-scores appeared, accurately discriminating low-risk (LR) from intermediate-risk (IR) and high-risk (HR) patients (98.7% negative predictive value [NPV], 97.2% sensitivity). Its prospective implementation guiding decision-making in an independent SOT cohort confirmed the very high NPV and sensitivity identifying LR patients. By integrating type of preventive therapy, patient age, and donor (D) and recipient (R) CMV-serostatus to the CMV-CMI risk-score, we generated a global risk-prognostic model showing accurate discrimination and calibration in both derivation (AUC: 0.807) and validation cohorts (AUC: 0.719). Conclusion: We developed a robust CMV-PrognosTIC score to quantify the risk of CMV infection in SOT, which may be readily implemented in clinical transplantation to personalize CMV preventive therapies.

Matèries

Immunologia de la trasplantació, Resposta immunitària

Matèries (anglès)

Transplantation immunology, Immune response

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

KERVELLA, Delphine, CASANOVA FERRER, Franc, KOTTON, Camille n., DONADEU, Laura, KUMAR, Deepali, PINEDA, Silvia, CRESPO, Elena, MENEGHINI, Maria, GONZÁLEZ-COSTELLO, José, GARCÍA ROMERO, Elena, LLADÓ, Laura, CACHERO, Alba, MELILLI, Edoardo, TORRES, Irina b., MARTÍNEZ LACALLE, Anna, CASTAÑEDA, Zaira, MARTINEZ-GALLO, Mónica, LEN, Óscar, LOS-ARCOS, Ibai, TRILLA HERRERA, Enric, MIRET, Enric, GIRAL, Magali, BROUARD, Sophie, GIRARDIN, François r., VILLARD, Jean, BUDDE, Klemens, LEFAUCHEUR, Carmen, LOUPY, Alexandre, MORESO, Francesc, BESTARD MATAMOROS, Oriol. A New Prognostic Score Based on Cell-Mediated Immunity for Cytomegalovirus Infection After Transplantation. _Kidney International Reports_. 2025. Vol. 10, núm. 9, pàgs. 3044-3057. [consulta: 25 de febrer de 2026]. ISSN: 2468-0249. [Disponible a: https://hdl.handle.net/2445/223518]

Exportar metadades

JSON - METS

Compartir registre